After backlash, EpiPen maker to help reduce patient costs

The embattled manufacturer of EpiPens said Thursday it would help extreme allergy sufferers meet the costs of the life-saving devices after a five-fold price hike sparked outrage. Mylan NV, which holds a near-monopoly on the manufacture of the epinephrine injectors, said it would expand existing programs to defray out-of-pocket costs but did not say it would lower prices. After a series of price hikes, a pack of two of the devices sells for more than $600, compared to less than $100 in 2007, when Mylan bought the rights to the technology.